SIRPA and pancreatic adenocarcinoma: Consistent with work from Matozaki and colleagues, who showed that treatment of renal tumors with a high-affinity anti-SIRPα antibody reduced tumor volume and increased CD8 T cell infiltration74 and macrophages,75 we showed a similar phenomenon (using a different antibody clone) in murine models of melanoma, pancreatic adenocarcinoma, and breast adenocarcinoma.